Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?

被引：2

作者：

Forni, Gian Luca ^{[1
]}

Kattamis, Antonis ^{[2
]}

Kuo, Kevin H. M. ^{[3
]}

Maggio, Aurelio ^{[4
]}

Sheth, Sujit ^{[5
]}

Taher, Ali T. ^{[6
]}

Viprakasit, Vip ^{[7
,8
]}

机构：

[1] ForAnemia Fdn, Via Garibaldi 7,3C, I-16124 Genoa, Italy

[2] Natl & Kapodistrian Univ Athens, Dept Pediat 1, Athens, Greece

[3] Univ Toronto, Div Hematol, Toronto, ON, Canada

[4] AOOR Villa Sofia V Cervello, Campus Haematol Franco & Piera Cutino, Palermo, Italy

[5] Weill Cornell Med, Dept Pediat, Div Hematol & Oncol, New York, NY USA

[6] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon

[7] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand

[8] Mahidol Univ, Siriraj Hosp, Fac Med, Thalassemia Ctr, Bangkok, Thailand

来源：

PEDIATRIC BLOOD & CANCER | 2024年 / 71卷 / 08期

关键词：

ferritin; heart; iron chelation; iron overload; liver; thalassemia; PEDIATRIC-PATIENTS; OPEN-LABEL; DEFERASIROX; EFFICACY; SAFETY; DEFERIPRONE; DESFERRIOXAMINE; TOLERABILITY; MULTICENTER; OVERLOAD;

D O I：

10.1002/pbc.31035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this review, we provide a summary of evidence on iron overload in young children with transfusion-dependent beta-thalassemia (TDT) and explore the ideal timing for intervention. Key data from clinical trials and observational studies of the three available iron chelators deferoxamine, deferiprone, and deferasirox are also evaluated for inclusion of subsets of young children, especially those less than 6 years of age. Evidence on the efficacy and safety of iron chelation therapy for children >= 2 years of age with transfusional iron overload is widely available. New data exploring the risks and benefits of early-start iron chelation in younger patients with minimal iron overload are also emerging.

引用

页数：7

共 50 条

[41] Anthropometric measurements in children having transfusion-dependent beta thalassemia [J].

Moiz, Bushra ;

Habib, Aysha ;

Sawani, Sobiya ;

Raheem, Ahmed ;

Hasan, Bilal ;

Gangwani, Manesh .

HEMATOLOGY, 2018, 23 (04) :248-252

[42] ASSESSMENT OF IRON ACCUMULATION IN CHILDREN WITH TRANSFUSION DEPENDENT B-THALASSEMIA [J].

Smetanina, N. S. ;

Tereshchenko, G., V ;

Krasilnikova, M., V ;

Gvozdev, A. A. ;

Ibragimova, D. I. ;

Mitrofanova, A. M. ;

Lokhmatova, M. E. ;

Novichkova, G. A. .

GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2016, 61 (01) :42-48

[43] Thalassemia-related complications in pediatric, adolescent, and young adult patients with transfusion-dependent thalassemia: A multicenter study in Thailand [J].

Surapolchai, Pacharapan ;

Songdej, Duantida ;

Hantaweepant, Chattree ;

Tantiworawit, Adisak ;

Charoenkwan, Pimlak ;

Lauhasurayotin, Supanun ;

Torcharus, Kitti ;

Sripornsawan, Pornpun ;

Sutcharitchan, Pranee ;

Konwilaisak, Patcharee ;

Saengboon, Supawee ;

Pongtanakul, Bunchoo ;

Teawtrakul, Nattiya .

PEDIATRIC BLOOD & CANCER, 2023, 70 (10)

[44] Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients [J].

Chawsamtong, Sriwatree ;

Jetsrisuparb, Arunee ;

Kengkla, Kirati ;

Jaisue, Siriluk .

PHARMACY PRACTICE-GRANADA, 2022, 20 (01)

[45] Hypoparathyroidism in transfusion-dependent patients with β-thalassemia [J].

Chern, JPS ;

Lin, KH .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (04) :291-293

[46] Effect of Iron Accumulation on Bone Mineral Density in Patients Diagnosed With Transfusion-Dependent Thalassemia [J].

Selim, Cem ;

Ciftciler, Rafiye ;

Kucukdiler, Ayse Hilal Eroglu ;

Karadag, Fatma Keklik ;

Soyer, Nur .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2025, 2025 (01)

[47] Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes [J].

Delforge, Michel ;

Selleslag, Dominik ;

Triffet, Agnes ;

Mineur, Philippe ;

Bries, Greet ;

Graux, Carlos ;

Trullemans, Fabienne ;

MacDonald, Karen ;

Abraham, Ivo ;

Pluymers, Wim ;

Ravoet, Christophe .

ANNALS OF HEMATOLOGY, 2011, 90 (06) :655-666

[48] Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response [J].

Hamed, Eman Mostafa ;

Meabed, Mohamed Hussein ;

Hussein, Raghda R. S. ;

Aly, Usama Farghaly .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (03) :179-193

[49] Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias [J].

Ho, P. J. ;

Tay, L. ;

Lindeman, R. ;

Catley, L. ;

Bowden, D. K. .

INTERNAL MEDICINE JOURNAL, 2011, 41 (07) :516-524

[50] A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan [J].

Ho, Wan-Ling ;

Chung, Kuo-Piao ;

Yang, Szu-Sheng ;

Lu, Meng-Yao ;

Jou, Shiann-Tarng ;

Chang, Hsiu-Hao ;

Yang, Yung-Li ;

Lin, Dong-Tsamn ;

Lin, Kai-Hsin .

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2013, 112 (04) :221-229

← 1 2 3 4 5 →